8.6 C
Byron Shire
August 14, 2022

Nurofen feels pain from false pill claims

Latest News

Criminalising protest

In another Sstate government descent into criminalising protest, to protect their own government’s sabotage of a liveable planet, last...

Other News

Mullumbimby Brunswick Valley footballers keep pressuring opposition Lennox Football Club

The Mullumbimby Brunswick Valley FC met up again with a much tougher Lennox FC in the Far North Coast...

A well-thought-out blend

Noy Ben Ami says that he ‘feels the vibe of the crowd and place’ before he starts to play his original music.

Evans Head, Iron Gates DA public planning meeting coming

The current development application (DA) for the flood and bushfire-prone site of the Evans Head, Iron Gates development will go before the Northern Rivers Planning Panel (NRPP) on 30 August.

Revoke Splendour consent

The legislation that gave Splendour consent has been revoked. Splendour’s consent should also now be revoked.  Originally Byron Council gave...

Police assault charge heads back to local court

The NSW Supreme Court has found that a decision by local magistrate and former police officer, Michael Deakin, was an ‘error of law’.

Concerns over future of Murwillumbah Hospital

Northern NSW Local Health District have sought to reassure locals that facilities won't be downgraded or closed at Murwillumbah Hospital when the controversial new Tweed Valley Hospital in Cudgen near Kingscliff opens in 2023.

Nurofen for period pain: the Federal Court has ruled against a range of identical but specially targeted, higher priced Nurofen products, saying they are ripping off customers.
Nurofen for period pain: the Federal Court has ruled against a range of identical but specially targeted, higher priced Nurofen products, saying they are ripping off customers.

The consumer watchdog has given Nurofen a major headache.

The painkiller-maker has been ordered to pull its targeted pain relief range off shop shelves and could be fined more than $1 million after the Federal Court ruled it misled consumers.

Reckitt Benckiser, the company behind Nurofen, has admitted to peddling identical products that were marketed to treat specific types of pain, and for almost double the price.

The competition watchdog launched court action against the UK-based pharmaceutical giant earlier this year, alleging Nurofen’s treatments for back pain, period pain, migraine pain and tension headaches all contained the same active ingredient, ibuprofen lysine 342mg.

Nurofen spokesperson Montse Pena said Nurofen did not set out to mislead consumers.

“Nurofen has co-operated with the ACCC in relation to these proceedings and will fully comply with the court order made today,” she said in a statement on Monday.

Australian Competition and Consumer Commission chairman Rod Sims said the price of Nurofen’s targeted pain relief range was significantly higher than similar painkillers.

“The Nurofen specific pain products were being sold at retail prices almost double that of Nurofen’s standard ibuprofen products and the general pain relief products of its competitors,” he said.

The Federal Court has ordered Reckitt Benckiser to remove the products from stores within three months and amend packets so consumers know that other painkillers are just as suitable.

The multinational was also ordered to publish website and newspaper articles to clarify the status of the drugs, introduce a consumer protection compliance program and pay the ACCC’s legal costs.

A court hearing about a likely fine is yet to be scheduled, but there are penalties of up to $1.1 million per offence.

“I imagine there is more than one contravention … but the penalties clearly should be significant,” Mr Sims said.

Ms Pena said Nurofen’s targeted range was launched to help consumers work out their pain relief options, “particularly within the grocery environment where there is no healthcare professional to assist decision making”.

But Mr Sims said the company was taking advantage of people’s medical ignorance for profit.

“They were clearly, in our view, trying to mislead consumers to buy something they might not otherwise have bought, and pay more for it,” he said.

He said any representations which are difficult for a consumer to test will now face greater scrutiny from the ACCC.

“We’re definitely having a crackdown on (companies) misleading consumers about health claims,” Mr Sims said.

“There’ll be more cases in the new year.”

Australian Pain Management Association chief executive Elizabeth Carrigan welcomed the Federal Court’s decision, saying people living with pain are vulnerable to Reckitt Benckiser’s “exploitative” pricing regime.

“We hope that the penalty to be imposed by the court will be sufficiently sizeable to dissuade other companies from making unsubstantiated claims,” she said.

Support The Echo

Keeping the community together and the community voice loud and clear is what The Echo is about. More than ever we need your help to keep this voice alive and thriving in the community.

Like all businesses we are struggling to keep food on the table of all our local and hard working journalists, artists, sales, delivery and drudges who keep the news coming out to you both in the newspaper and online. If you can spare a few dollars a week – or maybe more – we would appreciate all the support you are able to give to keep the voice of independent, local journalism alive.


Please enter your comment!
Please enter your name here

Mullum pods

First, Hans Lovejoy’s article ‘emergency wedged’ was educational, factual and provided valuable information to the community. Michele Grant’s letter (27 July) was emotive overgeneralisations...

Flood residents get $650 from Lismore Council

Lismore City Mayor Steve Krieg today announced that 1,558 residents will receive a grant of $650 from the Lismore Flood Appeal.

Barilaro begs off today’s Upper House committee inquiry

Today's scheduled hearing for the Upper House committee inquiry into the appointment of Mr John Barilaro as Senior Trade and Investment Commissioner to the Americas has been cancelled.

The COVID-19 Booster: Latest news from the pandemic

The COVID-19 Booster is Cosmos Magazine’s weekly shot of the latest research, news and data from the pandemic.